StrongLink Intelligence Secures Hundreds of Millions in Series C Funding to Advance AI-Driven Integrated Solutions for Stroke Diagnosis and Treatment

VCBeat has learned that Union Strong (Beijing) Tech. Co. Ltd. (“Union Strong” or the “Company”), a leading domestic provider of integrated intelligent diagnosis and treatment solutions for cerebrovascular diseases, has announced the completion of its Series C financing round, amounting to hundreds of millions of RMB. The round was led by HongShan, with existing shareholders BioTrack Capital, Qinglan Fund, YuanBio Venture Capital, and Sunland Capital making additional investments. China Renaissance and Probe Capital served as financial advisors in this transaction.

In recent years, stroke has become the leading cause of death among the Chinese population. According to the "2019 Report on Stroke Prevention and Treatment in China" released by the Stroke Prevention and Control Project Committee of the National Health Commission, the lifetime risk of stroke in China ranks first globally at 39.9%, with a clear trend toward younger onset. Although millions of stroke cases receive clinical diagnosis and hundreds of thousands receive clinical treatment annually, 99% of unruptured intracranial aneurysms (UIAs) remain undetected in clinical practice, and 70% of acute ischemic stroke (AIS) cases with large vessel occlusion fail to receive effective treatment. Patients who are not identified early or treated promptly face extremely high rates of mortality and disability after stroke onset. This not only imposes a heavy burden on patients and their families but also places significant pressure on national medical insurance expenditures.

Union Strong^®Founded in September 2016, the company has undertaken national and provincial/ministerial-level research projects, including major projects under the “13th Five-Year Plan.” In collaboration with renowned neurology experts from leading hospitals such as Xuanwu Hospital, Tiantan Hospital, Changhai Hospital, and Huashan Hospital, it has spent several years conducting rigorous scientific research and clinical validation. Together, they have developed an integrated intelligent diagnosis and treatment platform for hemorrhagic and ischemic stroke, powered by cutting-edge artificial intelligence algorithms. The platform provides AI-driven products and services covering the entire care continuum for cerebrovascular disease patients, including automated screening, precise diagnosis, intelligent surgical planning, intraoperative assistance, and postoperative follow-up.

The company has obtained NMPA registration certificates for two products, with its latest product being UKnow.^®The surgical planning software for intracranial aneurysms was approved through the National Medical Products Administration’s (NMPA) Green Channel for Innovative Medical Devices this April, and is poised to obtain China’s first Class III registration certificate for AI-assisted treatment. Meanwhile, leveraging the U-Pixel™ AI Cloud Platform for Stroke Diagnosis and Treatment, it has already been deployed in hundreds of hospitals, serving thousands of patients.

In addition, Union Strong^®Entered into a comprehensive strategic partnership with GE HealthCare, a global leader in medical equipment, and collaborated deeply with its CT Product Division on acute cerebral infarction—the most prevalent condition—to provide UGuard, an AI-based diagnostic system for ischemic stroke.^®, significantly improving the diagnostic and treatment efficiency and cure rates of stroke centers in China; in collaboration with the DSA Product Division, it launched the first AI-powered intelligent angiography system for neurointervention, empowering more primary care hospitals. In the future, Union Strong^®We will also collaborate with more partners to jointly promote the intelligent prevention and treatment of cerebrovascular diseases in China, and establish intelligent stroke centers.

Union Strong^®Qin Lan, Founder and Chairman, stated: “China’s healthcare industry is currently undergoing accelerated transformation. The volume-based procurement and price reductions for drugs and consumables will significantly alleviate the medical burden on patients and the state, further promoting the inclusiveness and accessibility of healthcare. Meanwhile, the government is vigorously advancing priority approval processes for various innovative medical devices, aiming to foster high-quality, originally developed and independently innovated medical products in China. Union Strong^®, as the first company in China to focus on an integrated AI solution for the diagnosis and treatment of stroke prevention and emergency care, it possesses a comprehensive portfolio of stroke-related products. It not only maintains global leadership in numerous algorithmic technologies but also enables high-quality AI diagnostic and therapeutic services to reach primary healthcare facilities through large-scale promotion and application. This ensures that tens of millions of cerebrovascular disease patients and nearly 100 million individuals at high risk of stroke in China receive more timely and effective treatment, thereby improving cure rates, reducing mortality and disability rates, and lowering overall medical expenditures.

Yang Yunxia, Partner at HongShan, stated, “China currently has approximately 50 million individuals at high risk for stroke, creating a substantial demand for precise diagnosis and risk assessment among affected populations. A comprehensive AI solution for stroke will undoubtedly play a critical role throughout the entire continuum of care, including prevention, emergency response, diagnosis, and treatment. Union Strong^®“Collaborating with top domestic experts, we addressed critical pain points in treatment and extended our solutions upstream to intelligent screening and diagnosis, and downstream to patient follow-up assessment and smart therapy, thereby creating an integrated intelligent diagnosis and treatment platform for stroke.”

Chen Penghui, Partner at BioTrack Capital, stated: “We highly recognize Union Strong^®“BioTrack Capital and its founders are bullish on the significant market potential of AI in the neurology sector. Currently, both the maturity of the company’s products and its proven business model are at the forefront of the industry. As an existing shareholder, BioTrack Capital is pleased to have the opportunity to participate in this round of financing.”

Liu Xiao, Executive Director of YuanBio Venture Capital, stated: “It is an honor that YuanBio Beijing Angel Fund jointly led the investment in Union Strong this February.”^®Following the Series B+ round, YuanBio’s RMB master fund once again participates in Union Strong^®Union Strong's Series C financing round.^®“Over the past six months, the team has made significant progress in product development, clinical research, and commercialization, further solidifying its position as a leading AI enterprise for stroke care in China. We remain firmly optimistic about the company’s ability to leverage its interdisciplinary expertise, continuously strengthen its competitive advantages in medical data, algorithms, and the integration of medicine and engineering, and establish barriers in product promotion, thereby benefiting the vast population of patients with cerebrovascular diseases and stroke in China.”

Nie Hongxin, Partner at Sunland Capital, stated: “Sunland Capital is committed to Union Strong^®The decision to continue investing in this funding round is driven by our investment in Union Strong.^®Since then, we have witnessed the strong execution and learning-evolution capabilities of the Union Strong team.^®As China's largest AI-powered platform for stroke diagnosis and treatment, we will continue to collaborate closely in the precise diagnosis and clinical management of cerebrovascular diseases to benefit patients. We are delighted to continue our support for Union Strong.^®This top-tier team continues to pioneer and upgrade the field of intelligent diagnosis and treatment for cerebrovascular diseases in China. Sunland will continue to support Union Strong.^®...provide full support and empowerment during its rapid development.”

As the financial advisor for this transaction, Li Gang, Partner at China Renaissance, stated: “Union Strong^®“This is a company with which we established contact at a very early stage and have closely monitored over the long term. The growth of its founding team has paralleled the development of China’s neuro-interventional industry. We greatly appreciate the founding team’s focus on the neurological field and their nearly 20 years of deep industry engagement, supporting physicians’ professional development. They possess extensive industry experience and resources across multiple dimensions, including academic promotion, market education, hospital market access, and government affairs—factors that are indispensable for the rapid development of the emerging field of medical artificial intelligence. Furthermore, we are optimistic about the company’s product portfolio, which covers the entire diagnosis and treatment pathway for both hemorrhagic and ischemic diseases. By leveraging artificial intelligence to effectively address pain points in clinical diagnosis and treatment, the company demonstrates clear clinical value. We are pleased to have assisted the company in completing this round of financing and look forward to seeing it accelerate product pipeline progress and further advance large-scale commercialization post-financing. China Renaissance will continue to work closely with the company to expedite its development, provide more high-quality products for clinical use, and benefit the vast number of cerebrovascular disease patients in China.”

As the financial advisor for this transaction, Zhang Chen, Partner at Probes Capital, stated, “Artificial intelligence is reshaping every aspect of healthcare. From the construction of medical informatics infrastructure to assisted diagnosis, AI products have made significant strides. Assisted therapy will be the next key application direction, featuring higher technical barriers. In the field of cerebrovascular diseases, which is characterized by substantial demand and high complexity, intelligent innovative products based on deep learning and hemodynamic analysis will better assist clinicians and benefit patients. Probes Capital is honored to continue serving Union Strong.”^®, we believe the company will become a globally leading platform-based enterprise in intelligent clinical diagnosis and treatment for cerebrovascular diseases, and Probe Capital will continue to support Union Strong.^®rapid development.”

HongShan has always been committed to helping entrepreneurs build enduring, great companies by bringing rich global resources and valuable historical experience to its portfolio companies. HongShan has invested in numerous innovative enterprises and leaders shaping industry trends. As “entrepreneurs behind entrepreneurs,” HongShan focuses on investment opportunities in three sectors: technology/media, healthcare, and consumer goods/services. Over the past 16 years, HongShan has invested in nearly 600 companies characterized by distinct technological advantages, innovative business models, and high growth potential.

BioTrack Capital, established in 2017, is a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. We are not just investors; we are long-term partners to entrepreneurs. We provide sustained support to the most distinguished healthcare founders, fostering the next generation of leading enterprises in China’s healthcare industry.

YuanBio Venture Capital is an investment firm focused on early-stage and growth-stage companies in the healthcare and medical sectors. Headquartered at Suzhou BioBAY, it maintains a global reach. The firm currently manages approximately RMB 7 billion in assets and has completed investments in over 100 high-quality projects, primarily spanning new drug development, medical devices, in vitro diagnostics (IVD), and healthcare services. YuanBio has delivered substantial investment returns and has been repeatedly recognized as one of the Top 10 Venture Capital Funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together a team of seasoned professional investors and world-class scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and related fields. Leveraging its focused strategy and rich industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Sunland Capital is a professional investment fund focused on early-stage and growth-stage investments in the healthcare industry. With offices in Shanghai and Beijing, the firm targets high-growth sub-sectors such as biopharmaceuticals, medical devices (including in vitro diagnostics and gene technologies, minimally invasive interventional devices, implantable devices, minimally invasive surgical instruments, and medical robots), and healthcare services. Sunland Capital has invested in nearly 40 leading healthcare companies, including Guoke Hengtai, Aupu Biology, Deepwise Medical, Shengshi Taike, Baichen Medical, Zhishan Medical, Union Strong, Weike Medical, Ligatai, and Langhe Medical. The firm’s core team comprises founders of publicly listed healthcare companies, as well as professionals specializing in financial and strategic investment. Sunland Capital provides value-added services to its portfolio companies across various domains, including strategy formulation, talent acquisition, R&D, marketing, legal and regulatory compliance, mergers and acquisitions, IPOs, and industry association resources. Additionally, it assists portfolio companies in integrating advanced international technologies and establishing global operational concepts and standards, thereby driving continuous innovation and development.

Greenwaters Fund, established in 2020 and headquartered in Hangzhou, is a venture capital firm focused on the healthcare sector. The fund continuously seeks innovative biotechnologies and medical models, aiming to help address unmet clinical needs, provide long-term support for the growth of innovative enterprises, and jointly drive industry progress.